Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 318940. Отображено 100.
05-01-2012 дата публикации

Dendrimer based nanodevices for therapeutic and imaging purposes

Номер: US20120003155A1

A nanodevice composition including N-acetyl cysteine linked to a dendrimer, such as a PAMAM dendrimer or a multiarm PEG polymer, is provided. Also provided is a nanodevice for targeted delivery of a compound to a location in need of treatment. The nanodevice includes a PAMAM dendrimer or multiarm PEG polymer, linked to the compound via a disulfide bond. There is provided a nanodevice composition for localizing and delivering therapeutically active agents, the nanodevice includes a PAMAM dendrimer or multiarm PEG polymer and at least one therapeutically active agent attached to the PAMAM dendrimer or multiarm PEG polymer. A method of site-specific delivery of a therapeutically active agent, by attaching a therapeutically active agent to a PAMAM dendrimer or multiarm PEG polymer using a disulfide bond, administering the PAMAM dendrimer or multiarm PEG polymer to a patient in need of treatment, localizing the dendrimer or multiarm PEG polymer to a site in need of treatment, and releasing the therapeutically active agent at the site in need of treatment.

Подробнее
05-01-2012 дата публикации

Pyrazolo[1,5-a]pyrimidines for antiviral treatment

Номер: US20120003215A1
Принадлежит: Gilead Sciences Inc

The invention provides compounds of Formula I or Formula II: or a pharmaceutically acceptable salt or ester, thereof, as described herein. The compounds and compositions thereof are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.

Подробнее
05-01-2012 дата публикации

Recombinant fusion protein and polynucleotide construct for immunotoxin production

Номер: US20120003223A1
Автор: Itai Benhar, Yariv Mazor
Принадлежит: Ramot at Tel Aviv University Ltd

The present invention relates to a polynucleotide construct encoding a fusion protein consisting of a domain which binds the immunoglobulin Fc region, genetically fused to a truncated form of Pseudomonas exotoxin A (PE). In particular, the invention discloses the fusion protein, ZZ-PE38, and further provides immunotoxins, formed from complexes of the fusion protein with antibodies for targeted cell killing.

Подробнее
05-01-2012 дата публикации

Enterovirus Vaccines for Preventing or Treating Type 1 Diabetes (III)

Номер: US20120003240A1
Принадлежит: Sanofi Pasteur Inc, Vactech OY

Coxsackie B virus CBV1 has been found to be strongly associated with the risk of contracting type 1 diabetes. A vaccine comprising CBV1, a component thereof or an antibody thereto is provided for use in preventing or treating type 1 diabetes. In addition CBV2 was also found to be diabetogenic.

Подробнее
05-01-2012 дата публикации

Tuberculosis antigens, immunogenic compositions, diagnostics and methods related to the same

Номер: US20120003256A1
Принадлежит: Gene Therapy Systems

Provided herein are Mtb polynucleotides, recombinant Mtb peptides and polypeptides, immunogenic Mtb antigens, and Mtb antibodies. Immunogenic compositions are also provided that may be useful as recombinant, subunit and DNA vaccines. In addition the invention provides kits comprising Mtb polynucleotides, Mtb polypeptides, Mtb antibodies, and combinations thereof.

Подробнее
05-01-2012 дата публикации

Recombinant avian infectious coryza vaccine and process for preparing same

Номер: US20120003257A1

A recombinant avian infectious coryza vaccine and a process for preparing the same are provided. A process for preparing a recombinant avian infectious coryza vaccine which comprises step of constructing E. coli that may produce as an inclusion body a fusion peptide consisting of peptides derived from outer-membrane protein of Avibacterium paragarinarum serotype A and serotype C, step of culturing said E. coli and colleting and purifying inclusion body from culture, and step of preparing a preparation comprising said purified inclusion body, and an avian infectious coryza vaccine comprising as an active ingredient the fusion peptide. A linker sequence may be inserted between the respective peptides comprising the fusion peptide. For the peptide derived from the serotypes A and C, an amino acid sequence region of Region 2 or its vicinity responsible for protection from infection may be used.

Подробнее
05-01-2012 дата публикации

Immunogenic compositions for inducing an immune response to hiv

Номер: US20120003265A1
Принадлежит: WYETH LLC

The invention relates to immunogenic compositions for inducing an immune response to HIV comprising combinations of two, three, or four plasmids, where each plasmid is expressing a defined antigen, which may be a single antigen or a fusion of two or three antigens.

Подробнее
05-01-2012 дата публикации

Compositions Produced Using Enteric Pathogens and Methods of Use

Номер: US20120003269A1
Принадлежит: Epitopix LLC

The present invention provides compositions including polypeptides having the characteristics of polypeptides expressed by a reference microbe such E. coli or Salmonella . Examples of Salmonella strains that can be used include, for instance, S. enterica serovar Newport, S. enterica serovar Enteritidis, S. enterica serovar Typhimurium, and S. enterica serovar Dublin. Also provided are compositions including polypeptides having a particular molecular weight and a mass fingerprint that includes polypeptide fragments having a particular set of masses, or polypeptides having an amino acid sequence with at least about 95% identity with an amino acid sequence, wherein the polypeptide has seroreactive activity. The present invention also provides methods of making and methods of using such compositions.

Подробнее
05-01-2012 дата публикации

Composition Comprising Vascular Endothelial Growth Factor (VEGF) for the Treatment of Hair Loss

Номер: US20120003300A1
Принадлежит: Pangaea Laboratories Ltd

A composition to treat hair loss and enhance hair growth and condition. The composition comprises: i) one or more of VEGF, a VEGF biomimetic peptide, and/or a VEGFR2 receptor agonist; ii) ciclopirox olamine; and iii) a pharmaceutically acceptable carrier.

Подробнее
05-01-2012 дата публикации

Particles which are surface coated with hyaluronan or one of the derivatives thereof and the use of same as biological vectors for active substances

Номер: US20120003320A1

Particles comprising a core based on at least one biodegradable organosoluble polymer. At least a part of the surface of the particles is coated with at least one hyaluronan or a derivative thereof, the hyaluronan being a water-soluble, amphiphilic hyaluronan of which the carboxylic functions are in part transformed to form hydrophobic groups.

Подробнее
10-09-2005 дата публикации

МАЛАЯ РАСХОДНАЯ ЕМКОСТЬ С ПРЕПАРАТОМ ДЛЯ ТРАНСДЕРМАЛЬНОГО ВВЕДЕНИЯ НИКОТИНА

Номер: RU0000047853U1

1. Малая расходная емкость с препаратом для трансдермального введения никотина, содержащая трубчатый корпус, один конец которого закрыт прямолинейным соединительным швом, отличающаяся тем, что она дополнительно содержит крышку с винтовой резьбой, а на другом конце корпуса - коническую горловину с выпускным штуцером, содержащим винтовую резьбу и конический наконечник с выпускным отверстием диаметром от 1 до 2 мм и отношением диаметра выпускного отверстия к общей длине штуцера с наконечником от 1:10 до 1:15, причем в качестве пастообразного продукта она включает препарат для трансдермального введения никотина, включающий 4,0-12,0 мас.% нерастворимого в воде сополимера N-винилпирролидона с эфиром органической ненасыщенной кислоты, пропиленгликоль, производное целлюлозы, изопропилмиристат, стеариновую кислоту, аэросил, цетиловый спирт, никотин и этанол. 2. Малая расходная емкость с препаратом для трансдермального введения никотина по п.1, отличающаяся тем, что она выполнена из алюминия. РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 47 853 (13) U1 (51) МПК B65D 35/00 (2000.01) A61P 31/12 (1990.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ, ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ (12) ОПИСАНИЕ ПОЛЕЗНОЙ МОДЕЛИ К ПАТЕНТУ (21), (22) Заявка: 2004119300/22 , 01.07.2004 (24) Дата начала отсчета срока действия патента: 01.07.2004 (45) Опубликовано: 10.09.2005 (73) Патентообладатель(и): Тенгис Каш (DE) , Берт Уве Хартман (DE) , Тенгис Шаломович Якобашвили (RU) U 1 4 7 8 5 3 R U Ñòðàíèöà: 1 U 1 Формула полезной модели 1. Малая расходная емкость с препаратом для трансдермального введения никотина, содержащая трубчатый корпус, один конец которого закрыт прямолинейным соединительным швом, отличающаяся тем, что она дополнительно содержит крышку с винтовой резьбой, а на другом конце корпуса - коническую горловину с выпускным штуцером, содержащим винтовую резьбу и конический наконечник с выпускным отверстием диаметром от 1 до 2 мм и отношением диаметра выпускного отверстия к общей длине штуцера с ...

Подробнее
27-11-2009 дата публикации

УСТРОЙСТВО ДЛЯ ГРУППОВЫХ АППЛИКАЦИЙ ПРИ ГНОЙНО-НЕКРОТИЧЕСКИХ ПОРАЖЕНИЯХ ДИСТАЛЬНОЙ ЧАСТИ КОНЕЧНОСТЕЙ У КОРОВ

Номер: RU0000088969U1

Устройство для групповых аппликаций при гнойно-некротических поражениях дистальной части конечностей у коров, включающее животноводческие помещения для коров, санитарный блок для больных животных, прогон для перемещения животных из санитарного блока к ножным ваннам и из ножных ванн в санитарный блок, каскад ножных ванн, канализацию для сточной жидкости, сточную яму, задвижку трубопровода, трубопровод для дезинфицирующего раствора, клапан трубопровода, емкость для дезинфицирующего раствора, водопроводную систему животноводческих помещений. РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 88 969 (13) U1 (51) МПК A61P 31/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ, ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ (12) ОПИСАНИЕ ПОЛЕЗНОЙ МОДЕЛИ К ПАТЕНТУ (21), (22) Заявка: 2009124169/22, 24.06.2009 (24) Дата начала отсчета срока действия патента: 24.06.2009 (45) Опубликовано: 27.11.2009 8 8 9 6 9 R U Формула полезной модели Устройство для групповых аппликаций при гнойно-некротических поражениях дистальной части конечностей у коров, включающее животноводческие помещения для коров, санитарный блок для больных животных, прогон для перемещения животных из санитарного блока к ножным ваннам и из ножных ванн в санитарный блок, каскад ножных ванн, канализацию для сточной жидкости, сточную яму, задвижку трубопровода, трубопровод для дезинфицирующего раствора, клапан трубопровода, емкость для дезинфицирующего раствора, водопроводную систему животноводческих помещений. Ñòðàíèöà: 1 ru CL U 1 U 1 (54) УСТРОЙСТВО ДЛЯ ГРУППОВЫХ АППЛИКАЦИЙ ПРИ ГНОЙНО-НЕКРОТИЧЕСКИХ ПОРАЖЕНИЯХ ДИСТАЛЬНОЙ ЧАСТИ КОНЕЧНОСТЕЙ У КОРОВ 8 8 9 6 9 (73) Патентообладатель(и): Федеральное государственное образовательное учреждение высшего профессионального образования Курская государственная сельскохозяйственная академия имени профессора И.И. Иванова (RU) R U Адрес для переписки: 305021, г.Курск, ул. К. Маркса, 70, КГСХА, патентный отдел (72) Автор(ы): Елисеев Алексей Николаевич (RU), Истомин Сергей Алексеевич (RU), Степанов ...

Подробнее
27-12-2012 дата публикации

ГРАНУЛА ПРОТИВОТУБЕРКУЛЕЗНОГО ЛЕКАРСТВЕННОГО СРЕДСТВА

Номер: RU0000123325U1

Гранула противотуберкулезного лекарственного средства для перорального применения, состоящая из кишечнорастворимого покрытия и ядра, которое содержит изониазид и пара-аминосалицилат натрия и вспомогательные вещества, отличающаяся тем, что плотность гранулы варьируют от 0,9 до 1,05 г/мл, толщина кишечно-растворимого покрытия составляет 0,2-0,3 мм, размер частиц изониазида в ядре гранулы в 2-3 раза превышает размер частиц пара-аминосалицилата, а все частицы активных компонентов равномерно распределены в объеме ядра гранулы, и гранула содержит масло растительное гидрогенизированное, кросповидон, дисульфит натрия и метилцеллюлозу, которые так же равномерно распределенные в объеме ядра гранулы, при следующем содержании компонентов, мг: РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 123 325 U1 (51) МПК A61K 9/20 (2006.01) A61K 31/4409 (2006.01) A61K 31/616 (2006.01) A61P 31/06 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ (21)(22) Заявка: ПОЛЕЗНОЙ МОДЕЛИ К ПАТЕНТУ 2012128371/15, 06.07.2012 (24) Дата начала отсчета срока действия патента: 06.07.2012 (72) Автор(ы): Раджеш Шарма (RU) (73) Патентообладатель(и): Общество с ограниченной ответственностью "ЭДВАНСД ТРЕЙДИНГ" (RU) R U Приоритет(ы): (22) Дата подачи заявки: 06.07.2012 (45) Опубликовано: 27.12.2012 Бюл. № 36 пара-аминосалицилат натрия 500-900 изониазид 19-26 масло растительное гидрогенизированное кросповидон 1,1-1,5 22-31 дисульфит натрия 4-12 метилцеллюлоза 11-19 R U 1 2 3 3 2 5 Формула полезной модели Гранула противотуберкулезного лекарственного средства для перорального применения, состоящая из кишечнорастворимого покрытия и ядра, которое содержит изониазид и пара-аминосалицилат натрия и вспомогательные вещества, отличающаяся тем, что плотность гранулы варьируют от 0,9 до 1,05 г/мл, толщина кишечнорастворимого покрытия составляет 0,2-0,3 мм, размер частиц изониазида в ядре гранулы в 2-3 раза превышает размер частиц пара-аминосалицилата, а все частицы активных компонентов равномерно ...

Подробнее
05-01-2012 дата публикации

Homogenous preparations of il-28 and il-29

Номер: US20120004161A1
Принадлежит: Zymogenetics Inc

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

Подробнее
05-01-2012 дата публикации

Triheterocyclic Compounds and Compositions Thereof

Номер: US20120004224A1
Принадлежит: Gemin X Pharmaceuticals Canada Inc

The present invention relates to novel Triheterocyclic Compounds, compositions comprising a Triheterocyclic Compound, and methods useful for treating or preventing cancer or a neoplastic disorder comprising administering a Triheterocyclic Compound. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a cancer cell or neoplastic cell, treating or preventing a viral infection, or inhibiting the replication and/or infectivity of a virus.

Подробнее
05-01-2012 дата публикации

Compositions and methods for modulating activity of capped small rnas

Номер: US20120004279A1
Принадлежит: Leland Stanford Junior University

Compositions and methods for modulating transcription by RNA polymerases are described.

Подробнее
05-01-2012 дата публикации

Use Of Serine Protease Inhibitors In The Treatment Of Neutropenia

Номер: US20120004395A1
Принадлежит: MED DISCOVERY SA, Universitaet Zuerich

The invention relates to therapeutic compounds which are inhibitors of serine proteases, to pharmaceutical compositions thereof and to their use in the treatment of the human or animal body. More specifically, the present invention relates to a method for the treatment of neutropenia comprising the administration to a subject in need thereof of a therapeutically effective amount of a serine protease inhibitor. The invention also comprises prevention of apoptosis of myeloid cells (1) during and after transfection of bone marrow cells performed for gene therapy, (2) during blood stem cell mobilization performed for reconstitution of hematopoiesis and (3) during infusion of cells of the myeloid lineage for reconstitution of hematopoiesis for gene therapy or for treatment of neutropenia by infusion of neutrophils.

Подробнее
21-02-2017 дата публикации

Устройство с антибактериальными и кровоостанавливающими свойствами для оказания первой помощи при ранениях

Номер: RU0000168865U1

Полезная модель относится к медицине, а именно к устройствам, применяемым в медицине катастроф. Устройство с антибактериальными и кровоостанавливающими свойствами для оказания первой помощи при ранениях предназначено для оказания первой помощи в очаге катастрофы, а также для временной остановки наружного кровотечения при транспортировке пострадавшего. Авторы предлагают салфетку из гемостатических коллагеновых пластин в сочетании с антибактериальными и кровоостанавливающими препаратами, при этом оно состоит не менее чем из двух гемостатических коллагеновых пластин толщиной не менее 3 мм, при этом нижняя пластина покрыта смесью порошков цеолита и сульфаниламида в равных пропорциях толщиной не менее 1 мм, а верхняя пластина пропитана гентамицином из расчета 40 мг на 1 см пластины, салфетки могут быть упакованы в стерильную оболочку. РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 168 865 U1 (51) МПК A61L 15/32 (2006.01) A61L 15/44 (2006.01) A61K 31/7036 (2006.01) A61K 31/63 (2006.01) A61K 33/06 (2006.01) A61K 38/39 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА A61P 7/04 (2006.01) ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ A61P 31/04 (2006.01) (12) ОПИСАНИЕ ПОЛЕЗНОЙ МОДЕЛИ К ПАТЕНТУ (21)(22) Заявка: 2016131818, 03.08.2016 (24) Дата начала отсчета срока действия патента: 03.08.2016 (73) Патентообладатель(и): Рыбакова Маргарита Викторовна (RU) Дата регистрации: (56) Список документов, цитированных в отчете о поиске: SU 1705304 A1, 15.01.2002. US Приоритет(ы): (22) Дата подачи заявки: 03.08.2016 (45) Опубликовано: 21.02.2017 Бюл. № 6 U 1 R U Стр.: 1 U 1 (54) Устройство с антибактериальными и кровоостанавливающими свойствами для оказания первой помощи при ранениях (57) Реферат: Полезная модель относится к медицине, а антибактериальными и кровоостанавливающими именно к устройствам, применяемым в медицине препаратами, при этом оно состоит не менее чем катастроф. Устройство с антибактериальными и из двух гемостатических коллагеновых пластин кровоостанавливающими свойствами для толщиной не менее 3 мм, при этом ...

Подробнее
12-01-2012 дата публикации

Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection

Номер: US20120009148A1
Автор: Yoav Smith

Provided are methods of predicting responsiveness of a subject to interferon treatment, comprising comparing a level of expression in a cell of the subject of at least one gene selected from the group consisting KIR3DL3, KIR3DL2, KIR3DL1, KIR2DL1, KIR2DL2, KIR2DL3, KLRG1, KIR3DS1, CD160, HLA-A, HLA-B, HLA-C, HLA-F, HLA-G and IFI27 to a reference expression data of the at least one gene obtained from at least one interferon responder subject and/or at least one interferon non-responder subject. Also provided are methods and pharmaceutical compositions for treating a subject in need of interferon treatment.

Подробнее
12-01-2012 дата публикации

Compositions for bacterial mediated gene silencing and methods of using the same

Номер: US20120009153A1
Принадлежит: Individual

The invention features compositions and methods for delivering small interfering (siRNAs), e.g., shRNAs, to host cells using non-pathogenic strains of Salmonella bacteria containing nucleic acid expression constructs encoding shRNAs. In this process, shRNA expressed by the Salmonella silences or knocks down genes of interest (target genes) inside target cells. The nucleic acid expression constructs of the invention include an RNA polymerase (e.g., a T7 polymerase), an RNA polymerase promoter (e.g., a T7 polymerase promoter), and an RNA polymerase terminator (e.g., a T7 polymerase terminator). The Salmonella bacteria can also include, on the same or different nucleic acid construct, an endosomal release factor (e.g., HlyA).

Подробнее
12-01-2012 дата публикации

Immunoglobulin variants with altered binding to protein a

Номер: US20120009182A1
Принадлежит: Genentech Inc

Variant immunoglobulins with one or more amino acid modifications in the VH region that have altered binding to Staphylococcus aureus protein A, and methods of using the same are provided.

Подробнее
12-01-2012 дата публикации

Monoparamunity inducers based on attenuated rabbit myxomaviruses

Номер: US20120009217A1
Автор: Anton Mayr, Barbara Mayr
Принадлежит: Individual

The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals.

Подробнее
12-01-2012 дата публикации

Transfection of blood cells with mrna for immune stimulation and gene therapy

Номер: US20120009221A1
Принадлежит: CureVac AG

The present invention relates to a pharmaceutical composition containing blood cells or haemopoietic cells, e.g. red blood cells (erythrocytes), granulocytes, mononuclear cells (PBMCs) and/or blood platelets, in combination with a pharmaceutically acceptable excipient and/or vehicle, wherein the cells are transfected with at least one mRNA comprising at least one region coding for at least one antigen. The invention further discloses a method of preparing the aforesaid pharmaceutical composition and the use of blood cells transfected in this way for the preparation of drugs or pharmaceutical compositions for immune stimulation against the antigens encoded by the mRNA. The subjects according to the invention are used especially for the therapy and/or prophylaxis of carcinoses or infectious diseases and can also be employed in gene therapy.

Подробнее
12-01-2012 дата публикации

Prebiotic Formulations for use with Probiotics to Increase Probiotic Growth Rate and Activity

Номер: US20120009239A1
Принадлежит: MASTER SUPPLEMENTS Inc

Naturally occurring lecithins and/or oleic acid stimulate the growth and lactic acid producing activity of Lactobacillus and Bifidobacterium species of probiotic bacteria, and replace polysorbate 80 for those products. They can be used in naturally occurring form, or where they are to be combined with probiotics in a carrier, or they can be treated to yield a stable powdered form of these naturally oily compounds. They can be sold as combined prebiotic/probiotic formulations in the same carrier, or sold as separate dietary supplements, e.g., in capsule or tablet form, to be used with the probiotic formulation as desired.

Подробнее
12-01-2012 дата публикации

Respiratory Syncytial Virus Antigenic Compositions and Methods

Номер: US20120009254A1
Принадлежит: Artificial Cell Technologies Inc

Multilayer films comprise polypeptide epitopes from RSV. The multilayer films are capable of eliciting an immune response in a host upon administration to the host. The multilayer films include at least one designed peptide that includes one or more polypeptide epitopes from RSV. Specifically, the multilayer films include two polypeptide epitopes from RSV, such as an epitope that elicits a specific T-cell response such as a cytotoxic T-cell response, and an epitope that elicits a specific antibody response.

Подробнее
12-01-2012 дата публикации

Cell Penetrating Peptide Conjugates for Delivering of Nucleic Acids into a Cell

Номер: US20120010124A9
Принадлежит: Diatos SA

The invention provides cell penetrating peptide-nucleic acid conjugates having the formula P-L-N, wherein P is a cell penetrating peptide, N is a nucleic acid, preferably an oligonucleotide and more preferably a siRNA, and L is a hydrophilic polymer, preferably a polyethylene glycol (PEG)-based linker linking P and N together. Compositions, methods of use and methods for producing such conjugates are also disclosed.

Подробнее
12-01-2012 дата публикации

Recombinant surfactant protein d compositions and methods of use thereof

Номер: US20120010126A1
Принадлежит: Medical Research Council

We describe an rspd(n/CRD) polypeptide, fragment, homologue, variant or derivative thereof for use in a method of treatment or prophylaxis of a disease. A method of treating an individual suffering from a disease or preventing the occurrence of a disease in an individual is also described, in which the method comprises administering to the individual a therapeutically or prophylactically effective amount of an rspd (n/CRD) polypeptide, fragment, homologue, variant or derivative thereof. Preferably, the rspd (n/CRD) polypeptide and nucleic acid comprise SEQ ID NO: 1 and SEQ ID NO: 2, respectively.

Подробнее
12-01-2012 дата публикации

Novel cyclosporin analogues

Номер: US20120010131A1
Принадлежит: Scynexis Chemistry and Automation Inc

The invention relates to the use of cyclic compounds of general formula (I): wherein A, B, R 1 and R 2 are as defined in the specification, and their use as pharmaceuticals.

Подробнее
12-01-2012 дата публикации

Lactoferrin compositions and methods of wound treatment

Номер: US20120010150A1
Принадлежит: Agennix Inc

The present invention relates to lactoferrin compositions and methods of using the compositions to treat wounds. The compositions can be administered alone or in combination with other standard wound healing therapies.

Подробнее
12-01-2012 дата публикации

Tumor necrosis factor inhibiting peptides and uses thereof

Номер: US20120010158A1
Принадлежит: Panacea Biotec Ltd

The present invention relates to Tumor Necrosis Factor-alpha (TNF-alpha or TNF-α) inhibiting peptides and process for the preparation thereof. The present invention further relates to a pharmaceutical composition comprising TNF-alpha inhibiting peptides of the present invention and uses thereof in treating TNF-alpha mediated inflammatory disorders.

Подробнее
12-01-2012 дата публикации

"Methods of Reducing Nephrotoxicity in Subjects Administered Nucleoside Phosphonates"

Номер: US20120010170A1
Автор: George R. Painter
Принадлежит: Individual

A conjugate compound comprising an acyclic nucleoside phosphonate covalently coupled to a lipid for the therapeutic and/or prophylactic treatment of viral infection in an immunodeficient subject is described, along with compositions and methods of using the same. A preferred conugate compound is CMX001, having formula (I) or a pharmaceutically acceptable salt thereof.

Подробнее
12-01-2012 дата публикации

Nucleotide Analogue Prodrug and the Preparation Thereof

Номер: US20120010171A1
Автор: Jiandong Yuan

The present invention provides: 1) Derivative solid form of 9-[2-(R)-[bis[pivaloyloxymethoxy]-phosphinylmethoxy]propyl]adenine (bis-POM PMPA, abbreviated as TD hereinafter), including crystalline form A and form B of TD, TD fumarate salts and cyclodextrin inclusion complex of TD; 2) Synthesis and purification methods of TD and Solidification method of TD oil, including converting TD oil to crystalline TD in Form A and Form B, solid TD salts and cyclodextrin inclusion complex of TD; 3) Stable pharmaceutical compositions containing TD derivatives and their preparation; 4) The use of the above TD derivatives in the antiviral treatments, especially in the treatment of HIV, HBV, CMV, HSV-1, HSV-2 and human Herpes virus infections.

Подробнее
12-01-2012 дата публикации

Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials

Номер: US20120010187A1

The invention provides FIG. 1 novel antimicrobial chemical entities based on a nitrothiazolide backbone that exhibit antibacterial and antiparasitic action against a wide range of human pathogens. The new classes of compounds show extended action against Gram positive bacteria including MRSA drug resistant pathogens. In the Gram-positive organisms, they specifically target and functionally inhibit microbial attachment to surfaces and biofilm formation. In Gram-negative bacteria, including enteroaggregative E. coli strains, these compounds function as pilicides by inhibiting the assembly of pilin subunits into adhesive filaments. Several of these compounds show potent antimicrobial action against Gram positive bacteria, perhaps involving novel targets. Many of the benzothiophene derivatives exhibit antimicrobial activity in the low micrograms per ml range and in blocking biofilm formation in the nanomolar range; ranges considered are well within the range of utility as therapeutics.

Подробнее
12-01-2012 дата публикации

Anthranilamide derivatives as pesticides

Номер: US20120010250A1
Принадлежит: Bayer CropScience AG

The present invention relates to novel anthranilamide derivatives of the general formula (I) in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , A, Q, Y and n are each as defined in the description—, to the use thereof as insecticides and acaricides for control of animal pests, and to several processes for preparation thereof.

Подробнее
19-01-2012 дата публикации

Il-1beta binding antibodies and fragments thereof

Номер: US20120014967A1
Принадлежит: Xoma Technology Ltd USA

An IL-1β binding antibody or IL-1β binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1β binding polypeptide. IL-1β binding antibodies or IL-1β binding fragments thereof are provided which have desirable affinity and potency.

Подробнее
19-01-2012 дата публикации

Avirulent, immunogenic flavivirus chimeras

Номер: US20120014981A1

Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.

Подробнее
19-01-2012 дата публикации

PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS

Номер: US20120014989A1
Принадлежит: Incyte Corp

The present invention provides pyrrolo[2,3-b]pyridine-4-yl amines pyrrolo[2,3-b]pyrimidin-4-yl amines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer.

Подробнее
19-01-2012 дата публикации

Traditional chinese medicinal ointment for treating burn, scald and infective trauma and preparative method thereof

Номер: US20120015041A1
Автор: Xinwei Sun
Принадлежит: Individual

This invention is disclosing a pure ointment of traditional Chinese medicine which was invented to treat burn or scald, and infectious trauma, and its preparation. The ointment has solved a number of problems in the treatment of burn or scald, and infectious trauma, such as the high cost of current drugs, post-treatment scar, and unfavorable therapeutic effect. The advantages of this ointment include low cost, favorable therapeutic effect, short course, and without scar after treatment. Its formula is based on the weight of every five hundred portions of following ingredients: lithospermum, 4-10 portions, beeswax, 5-20 potions, insect-white wax, 5-20 portions, and lard, 450-486 portions.

Подробнее
19-01-2012 дата публикации

Complement receptor 2 targeted complement modulators

Номер: US20120015871A1

Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.

Подробнее
19-01-2012 дата публикации

Melanocortin analogs with antimicrobial activity

Номер: US20120015873A1
Принадлежит: Individual

The present invention finds application in the therapeutic fields. In particular, it concerns new synthetic melanocortin peptides having improved antimicrobial activity.

Подробнее
19-01-2012 дата публикации

Novel inhibitors of retroviral reverse transcriptace

Номер: US20120015874A1
Принадлежит: University of Missouri System

Disclosed are nucleic acid molecules, and methods of their use, which have a specific structure including a double helical domain and a G-quadruplex domain physically connected by a linker domain which may be nucleosidic or non-nucleosidic. These aptamers demonstrate potent inhibition of phylogenetically diverse primate lentiviral reverse transcriptases, which effect is largely independent of aptamer sequence provided that the aptamer has the specified structure.

Подробнее
19-01-2012 дата публикации

Sulfone Compounds Which Modulate The CB2 Receptor

Номер: US20120015988A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Compounds which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

Подробнее
19-01-2012 дата публикации

Pharmaceutical composition for external use

Номер: US20120015997A1
Принадлежит: Nihon Nohyaku Co Ltd, Pola Pharma Inc

Provided is a pharmaceutical composition for external use, including: (i) a compound represented by structural formula (2) and/or a salt thereof; and (ii) N-methyl-2-pyrrolidone.

Подробнее
19-01-2012 дата публикации

Phototherapy methods and devices comprising emissive aryl-heteroaryl compounds

Номер: US20120015998A1
Принадлежит: Nitto Denko Corp

Disclosed herein are compounds represented by a formula: R 1 —Ar 1 —X—Ar 2 —Ar 3 -Het, wherein R 1 , Ar 1 , X, Ar 2 , Ar 3 , and Het are described herein. Compositions and light-emitting devices related thereto are also disclosed.

Подробнее
19-01-2012 дата публикации

Enzymes and methods for producing omega-3 fatty acids

Номер: US20120016144A1
Принадлежит: Individual

The present invention relates generally to the field of recombinant fatty acid synthesis, particularly in transgenic plants. The application describes genes involved in fatty acid synthesis and provides methods and vectors for the manipulation of fatty acid composition of plant oils. In particular, the invention provides constructs for achieving the integration of multiple heterologous genes involved in fatty acid synthesis into the plant genome, such that the resulting plants produce altered levels of polyunsaturated fatty acids. Also described are methods for enhancing the expression of fatty acid biosynthesis enzymes by co-expressing a silencing suppressor within the plant storage organ.

Подробнее
26-01-2012 дата публикации

MHC-Less cells

Номер: US20120020885A1
Принадлежит: SEARETE LLC

The present disclosure relates to compositions, methods, systems, computer-implemented methods, and computer program products thereof that relate to biological cells for delivery of at least one therapeutic agent to a biological tissue or subject.

Подробнее
26-01-2012 дата публикации

Leukemia inhibitory factor (lif) for use in repressing human papillomavirus (hpv) transcription

Номер: US20120020914A1
Принадлежит: Leland Stanford Junior University

Embodiments of the invention are related to leukemia inhibitory factor (LIF) for use in repressing human papillomavirus (HPV) transcription. Processes and related kits are described for treating a HPV-associated papillomatous proliferation, for treating a HPV-associated genital, anal, vulvar, penile, oral, or laryngeal wart, for treating HPV-associated cervical dysplasia or cervical cancer, and for repressing HPV transcription, by administering LIF to a patient in need thereof. A related embodiment is treatment of HPV-16 by use of LIF.

Подробнее
26-01-2012 дата публикации

Vaccine

Номер: US20120020993A1
Принадлежит: UK Secretary of State for Defence

The present invention relates to a pharmaceutical formulation comprising lipopolysaccharide derived from Burkholderia thailandensis and its various uses, including but not limited to its use in the treatment and/or prophylaxis of meliodosis or amelioration of symptoms associated therewith, and/or glanders or amelioration of symptoms associated therewith.

Подробнее
26-01-2012 дата публикации

Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof

Номер: US20120021002A1
Принадлежит: New York University NYU

The present invention relates to an isolated Clostridial neurotoxin propeptide having a light chain region, a heavy chain region, where the light and heavy chain regions are linked by a disulfide bond, and an intermediate region connecting the light and heavy chain regions. An isolated nucleic acid molecule encoding a Clostridial neurotoxin propeptide is also disclosed. Also disclosed is an isolated, physiologically active Clostridial neurotoxin produced by cleaving a Clostridial neurotoxin propeptide, a vaccine or antidote thereof, and methods of immunizing against or treating for toxic effects of Clostridial neurotoxins. Methods of expressing recombinant physiologically active Clostridial neurotoxins are also disclosed. Also disclosed is a chimeric protein having a heavy chain region of a Clostridial neurotoxin and a protein with therapeutic functionality. A treatment method is also disclosed.

Подробнее
26-01-2012 дата публикации

Corrosion current-generating metal particulates and use thereof

Номер: US20120021014A1

Metal particulates capable of generating low levels of corrosion current beneficial for pharmaceutical, cosmetic and other medical uses are provided.

Подробнее
26-01-2012 дата публикации

Use of a synergistic combination of hypothiocyanite and/or hypohalite ions and lactoferrin for preparing a treatment for cystic fibrosis

Номер: US20120021071A1
Принадлежит: ALAXIA SAS

The invention relates to the use of a synergistic combination of at least one ion selected from the group including hypothiocyanites and/or hypohalites and of lactoferrin for preparing a pharmaceutical composition for treating cystic fibrosis. In one embodiment, the lactoferrin is one having a purity higher than 95% and substantially free of lipopolysaccharides, endotoxins, and angiogenins, and having an iron saturation level higher than 15%.

Подробнее
26-01-2012 дата публикации

Garcinia Mangostana L. and Iridoid Based Formulations

Номер: US20120021079A1
Принадлежит: Individual

Embodiments of the invention relate to fortified food and dietary supplement products, which may be administered to produce desirable physiological improvement. In particular, embodiments of the invention relate to the administration of products enhanced with Garcinia mangostana L. and iridoids.

Подробнее
26-01-2012 дата публикации

Antibiotic peptides

Номер: US20120021975A1
Принадлежит: AMP Therapeutics GmbH and Co KG

The invention relates to a peptide or peptide derivative having the general formula: Sub 1 -X 1 -D 2 K 3 -P 4 -P 5 -Y 6 -L 7 -P 8 -R 9 -P 10 -X 2 -P 12 -P 13 -R 14 -X 3 -I 16 -P 17 /Y 17 -N 18 -N 19 -X 4 -Sub 2 , wherein X 1 is a non-polar, hydrophobic group or a positively charged group, D 2 is asparagine or glutamine, K 3 , X 2 , and X 4 are positively charged groups, X 3 is a positively charged group, proline, or a proline derivative; L 7 and I 16 are non-polar, hydrophobic groups, Y 6 and Y 17 are tyrosine, R 9 and R 14 are arginine, N 18 and N 19 are asparagine or glutamine, P 4 , P 5 , P 8 , P 10 , P 12 , P 13 , and P 17 are proline, hydroxyproline, or derivatives thereof, wherein possibly one or two of the groups selected from D 2 , P 4 , P 5 , P 8 , P 10 , P 12 , P 13 , P 17 , and Y 17 are replaced by an arbitrary group and/or P 13 and R 14 are exchanged, Sub 1 is the free or modified N-terminus, and Sub 2 is the free or modified C-terminus. The invention further relates to the use of the peptides and peptide derivatives in medicine, as an antibiotic, in a disinfectant or cleaning agent, as a preservative or in a packaging material, in pharmaceutical research, or in a screening method.

Подробнее
26-01-2012 дата публикации

Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle

Номер: US20120022001A1
Автор: David F. Driscoll
Принадлежит: STABLE SOLUTIONS LLC

A method of parenterally administering a composition, the method including parenterally administering to a person a composition including at least one omega-3 fatty acid and at least one drug, wherein the at least one omega-3 fatty acid source and the at least one drug are administered simultaneously.

Подробнее
26-01-2012 дата публикации

Composition and methods of treatment of bacterial meningitis

Номер: US20120022031A1
Автор: Robert B. Boyd
Принадлежит: NBR PATHFINDER LLC

A diluted solution of ceftiofur sodium is intrathecally or ventricularly delivered to effectively treat bacterial meningitis while maintaining the patient's threshold and reducing the likelihood of seizure.

Подробнее
26-01-2012 дата публикации

Animal treatment formulation and methods of use

Номер: US20120022038A1
Принадлежит: Mastitis Res Centre Ltd

The present invention relates to a formulation for administration to the teat canal of the mammary gland of an animal, the formulation including: a physical barrier material, characterised in that the formulation includes sufficient antibiotic in relation to physical barrier material such that the formulation is configured to disintegrate over a period of time after administration to the teat canal.

Подробнее
26-01-2012 дата публикации

Bridged compounds as hiv integrase inhibitors

Номер: US20120022045A1
Принадлежит: Individual

Compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: the asterisk * in Q denotes the point of attachment to the rest of the compound; and n, L1, L2, X1, X2, χ3, Y, Z, R1, R2 and R3 are defined herein. The N compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset or progression of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se (or as hydrates or solvates thereof) or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Подробнее
26-01-2012 дата публикации

Derivatives of n-(arylamino)sulfonamides as inhibitors of mek

Номер: US20120022076A1
Принадлежит: Individual

This invention concerns N-(2-arylamino)aryl sulfonamides, which are inhibitors of MEK and are useful in treatment of cancer and other hyperproliferative diseases.

Подробнее
26-01-2012 дата публикации

Short Interfering Ribonucleic Acid (siRNA) for Oral Administration

Номер: US20120022139A1
Принадлежит: NOVARTIS AG

Short interfering ribonucleic acid (siRNA) for oral administration, said siRNA comprising two separate RNA strands that are complementary to each other over at least 15 nucleotides, wherein each strand is 49 nucleotides or less, and wherein at least one of which strands contains at least one chemical modification.

Подробнее
26-01-2012 дата публикации

Recombinant Anti-VLA4 Antibody Molecules

Номер: US20120022236A1
Принадлежит: BIOGEN IDEC MA INC

The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.

Подробнее
02-02-2012 дата публикации

Transdermal pharmaceutical preparations

Номер: US20120024743A1
Принадлежит: EGIS PHARMACEUTICALS PLC

The present invention relates to semisolid transdermal pharmaceutical preparation having enhanced stability and bioavailability, wherein the particles are coated by a volatile silicon oil component and the thus obtained suspension is dispersed in a gel or cream base.

Подробнее
02-02-2012 дата публикации

Method for alleviating intestinal problems and novel bacterial strains therefor

Номер: US20120027734A1
Принадлежит: Individual

The present invention relates to butyrate producing bacterial strains related to the species Buty{acute over (η)}coccus pullicaecorum to be used in the prevention and/or treatment of intestinal health problems. The present invention therefore provides methods and compositions that overcome the problems associated with the currently used methods for administering butyric acid in the treatment of intestinal health problems in humans and/or animals.

Подробнее
02-02-2012 дата публикации

Genetically programmable pathogen sense and destroy

Номер: US20120027786A1
Автор: Ron Weiss, Saurabh Gupta
Принадлежит: Massachusetts Institute of Technology

Aspects of the invention relate to compositions and methods for using recombinant cells to sense and destroy specific pathogens.

Подробнее
02-02-2012 дата публикации

Immunological herpes simplex virus antigens and methods for use thereof

Номер: US20120027790A1
Принадлежит: UNIVERSITY OF WASHINGTON

The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.

Подробнее
02-02-2012 дата публикации

Antibody gene transfer and recombinant aav therefor

Номер: US20120027798A1
Принадлежит: Nationwide Childrens Hospital Inc

The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver antibody genes to target cells in mammals. Administration of rAAV encoding antibodies that neutralize the HIV-1 virus is exemplified.

Подробнее
02-02-2012 дата публикации

Formulations of Viable Cells for Oral Delivery

Номер: US20120027811A1

This invention relates to solid formulations for the oral delivery of live microbial cells which comprise dried viable cells and small amounts of a bile acid binding agent, for example, an anion exchange resin such as cholestyramine. The presence of bile acid binding agents in the formulation significantly increases the survival of the cells in the intestinal tract and facilitates delivery of the viable cells to the intestine.

Подробнее
02-02-2012 дата публикации

Apj receptor compounds

Номер: US20120028888A1
Принадлежит: ANCHOR THERAPEUTICS Inc

The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor apelin, also known as the APJ receptor. The APJ receptor compounds are derived from the intracellular loops and domains of the the APJ receptor. The invention also relates to the use of these APJ receptor compounds and pharmaceutical compositions comprising the APJ receptor compounds in the treatment of diseases and conditions associated with APJ receptor modulation, such as heart diseases (e.g., hypertension and tension and heart failure, such as congestive heart failure), cancer, diabetes, stem cell trafficking, fluid homeostasis, cell proliferation, immune function, obesity, metastatic disease, and HIV infection.

Подробнее
02-02-2012 дата публикации

Isolation, Purification, and Structure Elucidation of the Antiproliferative Compound Coibamide A

Номер: US20120028905A1

Novel antiproliferative compounds, compositions comprising the same, and methods of use thereof are disclosed.

Подробнее
02-02-2012 дата публикации

Pyrazole compounds as crth2 antagonists

Номер: US20120028938A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to pyrazole compounds of formula (I) and pharmaceutically acceptable salts thereof having CRTH2-activity, wherein W, L 1 , L 2 , X, L 3 , Y, R 1 and R 2 are as defined in the specification and claims, to their use as medicaments and to pharmaceutical formulations, containing said compounds or containing a combination of said compounds with one or more active substances.

Подробнее
02-02-2012 дата публикации

Medicinal Cream Made Using Neomycin Sulphate, Betamethasone Valerate, And Chitosan, And A Process To Make The Same

Номер: US20120028942A1
Принадлежит: Apex Labs Private Ltd

The present invention is directed to a composition for treating bacterial skin infections & skin inflammation, along with skin rejuvenation. More particularly, the present invention relates to a pharmaceutical cream comprising a biopolymer, a corticosteroid and an antibacterial active ingredient. It discloses a composition for treating bacterial skin infections & skin inflammation, along with skin rejuvenation containing a) a biopolymer in the form of chitosan, b) a combination of active pharmaceutical ingredients (APIs), neomycin sulphate & betamethasone valerate used in treating bacterial skin infections & skin inflammations, c) a cream base containing primary and secondary emulsifiers, waxy materials, co-solvents, acids, preservatives, buffering agents, anti oxidants, chelating agents, and humectants and d) water. The active ingredients, namely chitosan, a corticosteroid Betamethasone Valerate, and an antibacterial agent Neomycin Sulphate, are incorporated in cream base for use in treating bacterial skin infections and skin inflammation due to allergy & itching, & wounds on human skin involving contacting human skin with the above identified composition.

Подробнее
02-02-2012 дата публикации

Nitroimidazooxazines and their uses in anti-tubercular therapy

Номер: US20120028973A1
Принадлежит: Global Alliance for TB Drug Development

The present invention relates to novel nitroimidazooxazines, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.

Подробнее
02-02-2012 дата публикации

Short Interfering Ribonucleic Acid (siRNA) for Oral Administration

Номер: US20120029052A1
Принадлежит: NOVARTIS AG

Short interfering ribonucleic acid (siRNA) for oral administration, said siRNA comprising two separate RNA strands that are complementary to each other over at least 15 nucleotides, wherein each strand is 49 nucleotides or less, and wherein at least one of which strands contains at least one chemical modification.

Подробнее
09-02-2012 дата публикации

4'-substituted nucleoside derivatives as inhibitors of hcv rna replication

Номер: US20120034184A1
Принадлежит: Individual

The present invention relates to the use of nucleoside derivatives of formula I wherein B signifies a 9-purinyl residue B1 of formula or a 1-pyrimidyl residue B2 of formula wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof; for the treatment of diseases mediated by the Hepatitis C Virus (HCV), for the preparation of a medicament for such treatment and to pharmaceutical compositions containing such compounds.

Подробнее
09-02-2012 дата публикации

Treatment of neurotrophic factor mediated disorders

Номер: US20120034193A1
Принадлежит: Phytopharm Ltd

An agent selected from A/B-cis furostane, furostene, spirostane and spirostene steroidal sapogenins and ester, ether, ketone and glycosylated forms thereof is used to induce self-regulated homeostasis of neurotrophic factors (NFs), for example BDNF and/or GDNF, NFs with limited and manageable side effects in a subject, by modulating NFs in a non-toxic manner under homeostatic control. An effective amount of at least one such agent is administered to the subject, particularly in the treatment or prevention of a range of NF-mediated disorders, particularly neurological, psychiatric, inflammatory, allergic, immune and neoplastic disorders, and in the restoration or normalisation of neuronal and other function in or in relation to any damaged or abnormal tissue, including when assisting tissue (for example, skin, bone, eye and muscle) healing and general skin, bone, eye and muscle health.

Подробнее
09-02-2012 дата публикации

Influenza Vaccines, Antigens, Compositions, and Methods

Номер: US20120034253A1
Принадлежит: Fraunhofer USA Inc

The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and compositions useful in inducing or enhancing an immune response agains influenza antigens. Provided are recombinant protein antigens, compositions, and methods for the production of such antigens in plants. In some embodiments, influenza antigens include hemagglutinin polypeptides, neuraminidase polypeptides, and/or combinations thereof.

Подробнее
09-02-2012 дата публикации

Formulation for Prevention and Treatment of Bacterial Infections and Preparation Thereof

Номер: US20120034325A1
Принадлежит: Individual

The invention provides a formulation for the prevention and treatment of bacterial infections by administering an effective amount of the formulation comprising an extract of at least one plant selected from Allium sativum, Acorus calamus, Alstonia scholaris, Carissa spinarum, Cissampelos pareria, Chenopodium ambrosioides, Moringa olifera, Paederia foetida, Shorea robusta, Piper nigrum, Pueraria tuberosa, Ocimum sanctum, Terminalia bellirica, Tinospora cordifolia and Zingiber officinale , and a combination thereof. The invention also provides a process for preparing and method of using the same.

Подробнее
09-02-2012 дата публикации

Compositions and methods for the treatment of immune related diseases

Номер: US20120035073A1
Принадлежит: Individual

The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.

Подробнее
09-02-2012 дата публикации

Antibiotic product, use and formulation thereof

Номер: US20120035121A1
Принадлежит: Shionogi Inc

An antibiotic product is comprised of at least two dosages forms, each of which has a different release profile, with the C max for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as one or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a C max at different times.

Подробнее
09-02-2012 дата публикации

Ophthalmic compositions and methods for treating ophthalmic conditions

Номер: US20120035148A1
Автор: Scott M. Whitcup
Принадлежит: Allergan Inc

Compositions, and methods of using such compositions, useful for placement, for example injection, into the interior of human or animal eyes are provided. Such compositions include a therapeutic component, such as one or more corticosteroids, a biocompatible polymeric component, and a solvent component.

Подробнее
09-02-2012 дата публикации

Substituted dihydropyrazolones and their use

Номер: US20120035151A1
Принадлежит: Bayer Pharma AG

The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and haematological diseases and kidney diseases, and for promoting wound healing.

Подробнее
09-02-2012 дата публикации

Modulators of Cellular Adhesion

Номер: US20120035154A1
Принадлежит: Sarcode Bioscience Inc

The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R 1 -R 4 , n, p, A, B, D, E, L and AR 1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).

Подробнее
09-02-2012 дата публикации

Preparation and application of novel antibacterial and anticancer compounds and their derivatives

Номер: US20120035206A1
Принадлежит: Individual

Novel antibiotic and anticancer compounds of formula I, II, III, IV, derivatives, ostereoisomer, racemic and noracemic mixture of ostereoisomer, or the pharmaceutically acceptable salts or solvates of these compounds are disclosed. The preparation, pharmaceutical composition and biological activity of these compounds are disclosed.

Подробнее
09-02-2012 дата публикации

Compound for the Treatment of Tuberculosis

Номер: US20120035219A1
Принадлежит: AstraZeneca AB

(5R)-3-[4-[1-[(2S)-2,3-dihydroxypropanoyl]-3,6-dihydro-2H-pyridin-4-yl]-3,5-difluoro-phenyl]-5-(isoxazol-3-yloxymethyl)oxazolidin-2-one, or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, for use in the treatment of Mycobacterium tuberculosis.

Подробнее
09-02-2012 дата публикации

Compounds useful as inhibitors of atr kinase

Номер: US20120035407A1
Принадлежит: Vertex Pharmaceuticals Inc

The present invention relates to pyrazine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula II: wherein the variables are as defined herein.

Подробнее
09-02-2012 дата публикации

Vaccine

Номер: US20120036589A1
Принадлежит: University of Stirling

The present invention is concerned with the development of a vaccine against Aeromonas hydrophila for use especially in fish. The invention provides an immunogenic S-layer protein of approximately 50 kDa of A. hydrophila for use in the development of a vaccine, as well as the nucleic acid encoding said protein and vaccines comprising said protein or nucleic acid encoding said protein.

Подробнее
16-02-2012 дата публикации

Anti-Hemagglutinin Antibody Compositions And Methods Of Use Thereof

Номер: US20120039899A1
Принадлежит: Theraclone Sciences Inc

The present invention provides novel human anti-Influenza antibodies and related compositions and methods. These antibodies are used in the prevention, inhibition, neutralization, diagnosis, and treatment of influenza infection.

Подробнее
16-02-2012 дата публикации

Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells

Номер: US20120039916A1
Принадлежит: BAYLOR RESEARCH INSTITUTE

Compositions and methods for enhancing an immune response with an adjuvant composition comprising: an anti-dendritic cell (DC)-specific antibody or fragment thereof conjugated to at least a portion of a TLR agonist; and a pharmaceutically acceptable carrier are disclosed herein. The conjugate and agonist are each comprised in an amount such that, in combination with the other, are effective to produce the immune response in a human or animal subject in need of immunostimulation.

Подробнее
16-02-2012 дата публикации

Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)

Номер: US20120039936A1
Автор: Paul Howley, Sonja Leyrer
Принадлежит: Individual

The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furthermore, the present invention provides recombinant MVA comprising an exogenous DNA sequence inserted into said new insertion site as medicine or vaccine.

Подробнее
16-02-2012 дата публикации

Compositions and methods for vaccine and virus production

Номер: US20120039939A1
Принадлежит: JOHNS HOPKINS UNIVERSITY

The present invention features methods of producing immunogenic compositions and viruses, methods of treating and preventing viral infection, and methods of producing an immune response using cells that express a polypeptide selected from the group consisting of: cdk13, siat7e, Iama4, cox15, egr1, gas6, map3k9, and gap43, and a virus.

Подробнее
16-02-2012 дата публикации

Methods Of Immune Modulation

Номер: US20120039945A1

The present invention provides compounds and compositions thereof that modulate the immune system.

Подробнее
16-02-2012 дата публикации

Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish

Номер: US20120040010A1
Принадлежит: Individual

The invention relates to a composition and a method for manufacturing semi-dry or dry particles containing a mucoadhesive polymer and a bioactive agent such as, but not limited to, an Immunogenic Substance (e.g., a vaccine), that allows the oral or nasal administration and delivery of the bioactive agent essentially unaltered to mucosal surfaces in the animal, including an aquatic animal.

Подробнее
16-02-2012 дата публикации

Inhibitors of hcv ns5a

Номер: US20120040977A1
Автор: Leping Li, Min Zhong
Принадлежит: Presidio Pharmaceuticals Inc

Provided herein are compounds, pharmaceutical compositions and combination therapies for inhibition of hepatitis C.

Подробнее
16-02-2012 дата публикации

Thiadiazole and oxadiazole derivatives, preparation thereof and therapeutic use thereof

Номер: US20120040984A1
Принадлежит: SANOFI SA

The invention relates to compounds of the formula (I) either (i) in the state of a base or an acid addition salt, or (ii) in the state of an acid or a base addition salt, as well as to a method for preparing same and to the therapeutic applications thereof.

Подробнее
16-02-2012 дата публикации

2-hydroxyethyl-1h-quinolin-2-one derivatives and their azaisosteric analogues with antibacterial activity

Номер: US20120040989A1
Принадлежит: ACTELION PHARMACEUTICALS LTD

The invention relates to antibacterial compounds of formula I wherein R 1 represents alkoxy; each of U and V represents CH and W represents CH or N, or U represents N, V represents CH and W represents N, or each of U and V represents N and W represents CH; R 2 represents hydrogen or fluorine when W represents CH or R 2 represents hydrogen when W represents N; A represents O or CH 2 ; Y represents CH or N; Q represents O or S; and n represents 0 or 1; and salts of such compounds.

Подробнее
16-02-2012 дата публикации

Process for making quinolone compounds

Номер: US20120041208A1
Принадлежит: Rib X Pharmaceuticals Inc

The present invention relates to the field of synthesizing anti-infective compounds. More particularly, the invention relates to synthesizing a family of quinolone compounds useful as anti-infective agents. The invention includes a process for preparing a quinolone compound wherein less than about 0.40% of dimeric impurity of the quinolone is produced.

Подробнее
23-02-2012 дата публикации

Long-Term Storage of Non-Glycosylated Recombinant Human G-CSF

Номер: US20120042613A1
Принадлежит: SANDOZ AG

The present invention provides a method for stable long-term storage of non-glycosylated recombinant human G-CSF, wherein an aqueous acetate or glutamate buffered G-CSF composition containing non-glycosylated recombinant human G-CSF and sorbitol is cooled to a temperature of −15° C. or below to obtain a frozen G-CSF composition, which frozen composition is then stored in the frozen state. The temperature of the frozen G-CSF composition is later increased to a temperature within the range of from 2° C. to 8° C. for a time selected to allow the G-CSF composition to thaw and to obtain a liquid G-CSF composition having a G-CSF content of at least 95% of the G-CSF content of the original composition.

Подробнее
23-02-2012 дата публикации

Human papilloma virus peptide-specific T-cell response for treatment of warts

Номер: US20120045413A1
Принадлежит: Kevin Kim, Mayumi Nakagawa, Thomas Horn

The inventors have treated human patients for warts by intralesional injection of Candida antigen to induce a delayed-type hypersensitivity response in the patients. This creates an immune response that recognizes the antigens of the human papilloma virus (HPV) found in and causing the warts. It was found that the patients showed a response to HPV type 57 L1 peptide 380-412 (a peptide consisting of amino acid residues 380-412 of the protein L1) and HPV type 57 protein E4 (E4 10-30). One embodiment of the invention provides a pharmaceutical composition comprising a polypeptide comprising (a) L1 380-412 (SEQ ID NO:3) or a fragment of at least 8 residues of SEQ ID NO:3 or (b) E4 10-30 (SEQ ID NO:4) or a fragment of at least 8 residues of E4 10-30 (SEQ ID NO:4), wherein the composition is immunogenic in humans.

Подробнее
23-02-2012 дата публикации

Engineered anti-il-13 antibodies, compositions, methods and uses

Номер: US20120045438A1
Принадлежит: Centocor Ortho Biotech Inc

The present invention relates to engineered antibodies immuno specific for human interleukin-13 (IL-13) protein or fragment thereof, as well as methods of making and using thereof, including therapeutic indications.

Подробнее
23-02-2012 дата публикации

Stabilized anti-respiratory syncytial virus (rsv) antibody formulations

Номер: US20120045456A1
Принадлежит: MEDIMMUNE LLC

The present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with RSV infection utilizing the liquid formulations of the present invention.

Подробнее
23-02-2012 дата публикации

Biomolecule Surface Display and Uses Thereof

Номер: US20120045473A1
Автор: Jimmy Kwang
Принадлежит: Temasek Life Sciences Laboratory Ltd

A vaccine for the treatment or prevention of a disease in a subject, wherein said disease is associated with an avian influenza virus, and wherein said vaccine comprises an expression vector comprising a nucleic acid encoding a hemagglutinin peptide, such that in use said hemagglutinin peptide is expressed by said expression vector in said subject.

Подробнее